JP2002533359A - 組換えアデノ随伴ウイルスベクターを用いる、心筋細胞への効率的かつ安定なインビボでの遺伝子移入 - Google Patents
組換えアデノ随伴ウイルスベクターを用いる、心筋細胞への効率的かつ安定なインビボでの遺伝子移入Info
- Publication number
- JP2002533359A JP2002533359A JP2000590483A JP2000590483A JP2002533359A JP 2002533359 A JP2002533359 A JP 2002533359A JP 2000590483 A JP2000590483 A JP 2000590483A JP 2000590483 A JP2000590483 A JP 2000590483A JP 2002533359 A JP2002533359 A JP 2002533359A
- Authority
- JP
- Japan
- Prior art keywords
- aav
- cardiomyocytes
- raav
- use according
- therapeutically effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 45
- 210000004413 cardiac myocyte Anatomy 0.000 title claims abstract description 42
- 239000013598 vector Substances 0.000 title claims abstract description 21
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 13
- 238000001727 in vivo Methods 0.000 title claims abstract description 8
- 238000012546 transfer Methods 0.000 title description 5
- 210000004351 coronary vessel Anatomy 0.000 claims abstract description 18
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 18
- 230000033115 angiogenesis Effects 0.000 claims abstract description 16
- 210000003748 coronary sinus Anatomy 0.000 claims abstract description 10
- 230000004663 cell proliferation Effects 0.000 claims abstract description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 230000037396 body weight Effects 0.000 claims description 10
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 6
- 206010003119 arrhythmia Diseases 0.000 claims description 5
- 210000001367 artery Anatomy 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000037803 restenosis Diseases 0.000 claims description 5
- 108020005544 Antisense RNA Proteins 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 4
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims description 4
- 230000006793 arrhythmia Effects 0.000 claims description 4
- 239000003184 complementary RNA Substances 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 3
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 3
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 3
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims description 3
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 108010068426 Contractile Proteins Proteins 0.000 claims description 2
- 108090000862 Ion Channels Proteins 0.000 claims description 2
- 102000003945 NF-kappa B Human genes 0.000 claims description 2
- 108010057466 NF-kappa B Proteins 0.000 claims description 2
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 2
- 108020004440 Thymidine kinase Proteins 0.000 claims description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 102000002585 Contractile Proteins Human genes 0.000 claims 1
- 101150021185 FGF gene Proteins 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000005681 phospholamban Human genes 0.000 claims 1
- 108010059929 phospholamban Proteins 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 108700026220 vif Genes Proteins 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 abstract description 10
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 6
- 208000009525 Myocarditis Diseases 0.000 abstract description 3
- 230000010473 stable expression Effects 0.000 abstract description 3
- 210000000663 muscle cell Anatomy 0.000 abstract description 2
- 230000017074 necrotic cell death Effects 0.000 abstract description 2
- 230000014509 gene expression Effects 0.000 description 21
- 239000013608 rAAV vector Substances 0.000 description 19
- 108700019146 Transgenes Proteins 0.000 description 18
- 238000010361 transduction Methods 0.000 description 15
- 230000026683 transduction Effects 0.000 description 15
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 230000010412 perfusion Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 8
- 230000000747 cardiac effect Effects 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 108010005774 beta-Galactosidase Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 210000005003 heart tissue Anatomy 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 239000013607 AAV vector Substances 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 2
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 1
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000008148 cardioplegic solution Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- -1 p2 7 Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11392398P | 1998-12-28 | 1998-12-28 | |
| US60/113,923 | 1998-12-28 | ||
| PCT/US1999/031093 WO2000038518A1 (en) | 1998-12-28 | 1999-12-28 | Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002533359A true JP2002533359A (ja) | 2002-10-08 |
| JP2002533359A5 JP2002533359A5 (https=) | 2007-02-22 |
Family
ID=22352321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000590483A Pending JP2002533359A (ja) | 1998-12-28 | 1999-12-28 | 組換えアデノ随伴ウイルスベクターを用いる、心筋細胞への効率的かつ安定なインビボでの遺伝子移入 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1139751A4 (https=) |
| JP (1) | JP2002533359A (https=) |
| AU (1) | AU763049B2 (https=) |
| CA (1) | CA2356551A1 (https=) |
| WO (1) | WO2000038518A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007161704A (ja) * | 2005-12-09 | 2007-06-28 | Koshi Tei | 神経損傷を処置するためのまたは神経細胞を再生するための組成物 |
| JP2009544698A (ja) * | 2006-07-25 | 2009-12-17 | セラドン・コーポレーション | 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745416B2 (en) * | 1995-04-11 | 2010-06-29 | The Regents Of The University Of California | Method for in vivo regulation of cardiac muscle contractility |
| CA2389524A1 (en) * | 1999-11-05 | 2001-05-17 | The Regents Of The University Of California | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| CA2419245A1 (en) * | 2000-08-17 | 2002-02-21 | Keiya Ozawa | Adeno-associated virus-mediated delivery of angiogenic factors |
| EP1870473A1 (en) * | 2000-08-17 | 2007-12-26 | Keiya Ozawa | Adeno-associated virus-mediated delivery of angiogenic factors |
| EP1324780A4 (en) | 2000-09-06 | 2005-06-22 | Univ Johns Hopkins | METHODS OF TREATING CARDIAC ARRHYTHMIA |
| WO2002098432A1 (en) * | 2001-06-01 | 2002-12-12 | The Brigham And Women's Hospital, Inc. | Methods of treating cardiac disorders |
| AU2003299204A1 (en) | 2002-10-02 | 2004-04-23 | The Johns Hopkins University | Focal calcium channel modulation |
| KR20100129295A (ko) | 2008-02-19 | 2010-12-08 | 셀라돈 코포레이션 | 심근 내 바이러스 벡터의 흡수를 개선시키기 위한 조성물 |
| AU2012258525B2 (en) * | 2011-05-26 | 2017-02-23 | University Of Washington | Cell and gene based methods to improve cardiac function |
| WO2019097001A1 (en) * | 2017-11-16 | 2019-05-23 | Universite D'aix-Marseille | Fgf10 for the treatment of heart diseases |
| US12460226B2 (en) | 2018-04-16 | 2025-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating duchenne muscular dystrophy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792483A (en) * | 1993-04-05 | 1998-08-11 | Vickers, Inc. | Injection molding machine with an electric drive |
| US6162796A (en) * | 1995-09-27 | 2000-12-19 | The Rockefeller University | Method for transferring genes to the heart using AAV vectors |
-
1999
- 1999-12-28 AU AU23942/00A patent/AU763049B2/en not_active Ceased
- 1999-12-28 CA CA002356551A patent/CA2356551A1/en not_active Abandoned
- 1999-12-28 EP EP99967703A patent/EP1139751A4/en not_active Ceased
- 1999-12-28 JP JP2000590483A patent/JP2002533359A/ja active Pending
- 1999-12-28 WO PCT/US1999/031093 patent/WO2000038518A1/en not_active Ceased
Non-Patent Citations (2)
| Title |
|---|
| JPN6010008664, ＫＡＰＬＩＴＴ，Ｍ．Ｇ． ｅｔ ａｌ, "Ｌｏｎｇ−ｔｅｒｍ ｇｅｎｅ ｔｒａｎｓｆｅｒ ｉｎ ｐｏｒｃｉｎｅ ｍｙｏｃａｒｄｉｕｍ ａｆｔｅｒ ｃｏｒｏｎａｒｙ ｉｎｆｕｓｉｏｎ ｏｆ ａｎ ａｄｅｎｏ−ａｓｓｏｃｉａｔｅｄ ｖｉｒｕｓ ｖ", Ａｎｎ Ｔｈｏｒａｃ Ｓｕｒｇ, 1996, Ｖｏｌ．６２， Ｎｏ．６, ｐ．１６６９−７６ * |
| JPN6010008665, ＭＡＥＤＡ，Ｙ． ｅｔ ａｌ, "Ｅｆｆｉｃｉｅｎｔ ｇｅｎｅ ｔｒａｎｓｆｅｒ ｉｎｔｏ ｃａｒｄｉａｃ ｍｙｏｃｙｔｅｓ ｕｓｉｎｇ ａｄｅｎｏ−ａｓｓｏｃｉａｔｅｄ ｖｉｒｕｓ （ＡＡＶ） ｖｅｃｔｏｒｓ", Ｊ Ｍｏｌ Ｃｅｌｌ Ｃａｒｄｉｏｌ, 199807, Ｖｏｌ．３０， Ｎｏ．７, ｐ．１３４１−８ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007161704A (ja) * | 2005-12-09 | 2007-06-28 | Koshi Tei | 神経損傷を処置するためのまたは神経細胞を再生するための組成物 |
| JP2009544698A (ja) * | 2006-07-25 | 2009-12-17 | セラドン・コーポレーション | 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入 |
| JP2014218509A (ja) * | 2006-07-25 | 2014-11-20 | セラドン・コーポレーション | 遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000038518A1 (en) | 2000-07-06 |
| AU763049B2 (en) | 2003-07-10 |
| WO2000038518A9 (en) | 2002-04-11 |
| EP1139751A4 (en) | 2003-03-19 |
| CA2356551A1 (en) | 2000-07-06 |
| EP1139751A1 (en) | 2001-10-10 |
| AU2394200A (en) | 2000-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7078387B1 (en) | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors | |
| CN1136920C (zh) | 基因转移介导的血管形成疗法 | |
| JP3487597B2 (ja) | 筋細胞内での発現のためのウイルス性組換え型ベクター | |
| US5792453A (en) | Gene transfer-mediated angiogenesis therapy | |
| JP2004313198A (ja) | 心筋及び血管平滑筋へのアデノウイルス介在遺伝子移入 | |
| US20020111324A1 (en) | Adeno-associated virus-mediated delivery of angiogenic factors | |
| JP2002502608A (ja) | 血管新生促進因子である血管内皮細胞成長因子：ｖｅｇｆの変異体 | |
| JP2002533359A (ja) | 組換えアデノ随伴ウイルスベクターを用いる、心筋細胞への効率的かつ安定なインビボでの遺伝子移入 | |
| CN100350979C (zh) | 核酸和血管活性剂相组合用于加强的基因投递 | |
| US20250143624A1 (en) | Ventricular Arrhythmias and Related Methods | |
| EP0928202A1 (en) | Non-invasive administration of adeno-associated viral vectors | |
| US6099831A (en) | Viral recombinant vectors for expression in muscle cells | |
| AU706050C (en) | Gene transfer-mediated angiogenesis therapy | |
| HK1094944A (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| AU2006200170A1 (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| HK1008979B (en) | Gene transfer-mediated angiogenesis therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100222 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100714 |